Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Cash Flow (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Net Cash Flow for 14 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 89.09% year-over-year to $5.1 million, compared with a TTM value of -$47.5 million through Dec 2025, down 206.99%, and an annual FY2025 reading of -$5.5 million, up 88.49% over the prior year.
  • Net Cash Flow was $5.1 million for Q4 2025 at Enanta Pharmaceuticals, up from -$12.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $52.6 million in Q3 2021 and bottomed at -$72.5 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$745300.0, with a median of -$156500.0 recorded in 2022.
  • The sharpest move saw Net Cash Flow skyrocketed 513.43% in 2021, then plummeted 2466.63% in 2023.
  • Year by year, Net Cash Flow stood at $41.9 million in 2021, then plummeted by 104.23% to -$1.8 million in 2022, then tumbled by 2466.63% to -$45.5 million in 2023, then surged by 203.65% to $47.1 million in 2024, then plummeted by 89.09% to $5.1 million in 2025.
  • Business Quant data shows Net Cash Flow for ENTA at $5.1 million in Q4 2025, -$12.5 million in Q3 2025, and -$15.4 million in Q2 2025.